275 related articles for article (PubMed ID: 33656809)
1. Antiviral prophylaxis against hepatitis B recurrence after liver transplantation: Current concepts.
Orfanidou A; Papatheodoridis GV; Cholongitas E
Liver Int; 2021 Jul; 41(7):1448-1461. PubMed ID: 33656809
[TBL] [Abstract][Full Text] [Related]
2. Nucleos(t)ide analog(s) prophylaxis after hepatitis B immunoglobulin withdrawal against hepatitis B and D recurrence after liver transplantation.
Cholongitas E; Goulis I; Antoniadis N; Fouzas I; Imvrios G; Giakoustidis D; Giouleme O; Papanikolaou V; Akriviadis E; Vasiliadis T
Transpl Infect Dis; 2016 Oct; 18(5):667-673. PubMed ID: 27421122
[TBL] [Abstract][Full Text] [Related]
3. Tenofovir/entecavir monotherapy after hepatitis B immunoglobulin withdrawal is safe and effective in the prevention of hepatitis B in liver transplant recipients.
Fernández I; Loinaz C; Hernández O; Abradelo M; Manrique A; Calvo J; Manzano M; García A; Cambra F; Castellano G; Jiménez C
Transpl Infect Dis; 2015 Oct; 17(5):695-701. PubMed ID: 26257166
[TBL] [Abstract][Full Text] [Related]
4. Hepatitis B prophylaxis post liver transplantation with newer nucleos(t)ide analogues after hepatitis B immunoglobulin discontinuation.
Cholongitas E; Vasiliadis T; Antoniadis N; Goulis I; Papanikolaou V; Akriviadis E
Transpl Infect Dis; 2012 Oct; 14(5):479-87. PubMed ID: 22624695
[TBL] [Abstract][Full Text] [Related]
5. High genetic barrier nucleos(t)ide analogue(s) for prophylaxis from hepatitis B virus recurrence after liver transplantation: a systematic review.
Cholongitas E; Papatheodoridis GV
Am J Transplant; 2013 Feb; 13(2):353-62. PubMed ID: 23137006
[TBL] [Abstract][Full Text] [Related]
6. Prevention of lamivudine-resistant hepatitis B recurrence after liver transplantation with entecavir plus tenofovir combination therapy and perioperative hepatitis B immunoglobulin only.
Karlas T; Hartmann J; Weimann A; Maier M; Bartels M; Jonas S; Mössner J; Berg T; Tillmann HL; Wiegand J
Transpl Infect Dis; 2011 Jun; 13(3):299-302. PubMed ID: 21159112
[TBL] [Abstract][Full Text] [Related]
7. Prophylactic managements of hepatitis B viral infection in liver transplantation.
Onoe T; Tahara H; Tanaka Y; Ohdan H
World J Gastroenterol; 2016 Jan; 22(1):165-75. PubMed ID: 26755868
[TBL] [Abstract][Full Text] [Related]
8. A Very Short Course of HBIg+NA Followed by Entecavir or Tenofovir Monotherapy Prevents HBV Recurrence in Low-Risk Liver Transplant Recipients.
Manini MA; Bruce M; Whitehouse G; Mazzarelli C; Considine A; Agarwal K; Suddle A; Fagiuoli S; Heaton N; Heneghan M
Transplant Proc; 2021; 53(1):207-214. PubMed ID: 32605776
[TBL] [Abstract][Full Text] [Related]
9. Successful clinical and virological outcomes of liver transplantation for HDV/HBV-related disease after long-term discontinuation of hepatitis B immunoglobulins.
Lenci I; Tariciotti L; Angelico R; Milana M; Signorello A; Manzia TM; Toti L; Tisone G; Angelico M; Baiocchi L
Clin Transplant; 2023 Jun; 37(6):e14971. PubMed ID: 36928864
[TBL] [Abstract][Full Text] [Related]
10. Review of the pharmacological management of hepatitis B viral infection before and after liver transplantation.
Cholongitas E; Papatheodoridis GV
World J Gastroenterol; 2013 Dec; 19(48):9189-97. PubMed ID: 24409047
[TBL] [Abstract][Full Text] [Related]
11. Limited hepatitis B immunoglobulin with potent nucleos(t)ide analogue is a cost-effective prophylaxis against hepatitis B virus after liver transplantation.
Singer GA; Zielsdorf S; Fleetwood VA; Alvey N; Cohen E; Eswaran S; Shah N; Chan EY; Hertl M; Fayek SA
Transplant Proc; 2015 Mar; 47(2):478-84. PubMed ID: 25769595
[TBL] [Abstract][Full Text] [Related]
12. The long-term efficacy of combining nucleos(t)ide analog and low-dose hepatitis B immunoglobulin on post-transplant hepatitis B virus recurrence.
Idilman R; Akyildiz M; Keskin O; Gungor G; Yilmaz TU; Kalkan C; Dayangac M; Cinar K; Balci D; Hazinedaroglu S; Tokat Y
Clin Transplant; 2016 Oct; 30(10):1216-1221. PubMed ID: 27409074
[TBL] [Abstract][Full Text] [Related]
13. Prophylaxis against hepatitis B virus recurrence after liver transplantation: a registry study.
Shen S; Jiang L; Xiao GQ; Yan LN; Yang JY; Wen TF; Li B; Wang WT; Xu MQ; Wei YG
World J Gastroenterol; 2015 Jan; 21(2):584-92. PubMed ID: 25593480
[TBL] [Abstract][Full Text] [Related]
14. Entecavir or tenofovir monotherapy prevents HBV recurrence in liver transplant recipients: A 5-year follow-up study after hepatitis B immunoglobulin withdrawal.
Manini MA; Whitehouse G; Bruce M; Passerini M; Lim TY; Carey I; Considine A; Lampertico P; Suddle A; Heaton N; Heneghan M; Agarwal K
Dig Liver Dis; 2018 Sep; 50(9):944-953. PubMed ID: 29735294
[TBL] [Abstract][Full Text] [Related]
15. Escape hepatitis B virus mutations in recipients of antibody to hepatitis B core antigen-positive liver grafts receiving hepatitis B immunoglobulins.
Roche B; Roque-Afonso AM; Sebagh M; Delvart V; Duclos-Vallee JC; Castaing D; Samuel D
Liver Transpl; 2010 Jul; 16(7):885-94. PubMed ID: 20583085
[TBL] [Abstract][Full Text] [Related]
16. The Role of Antiviral Prophylaxis in Preventing HBV and HDV Recurrence in the Setting of Liver Transplantation.
Battistella S; Zanetto A; Gambato M; Germani G; Senzolo M; Burra P; Russo FP
Viruses; 2023 Apr; 15(5):. PubMed ID: 37243124
[TBL] [Abstract][Full Text] [Related]
17. Minimization of anti-hepatitis B surface antigen immunoglobulins for prophylaxis of hepatitis B viral recurrence in the first month after liver transplantation: the meaning of HBsAg quantitative level at the time of transplant.
Tandoi F; Nada E; Pittaluga F; Fop F; Lupo F; Romagnoli R; Salizzoni M
Transplant Proc; 2014 Sep; 46(7):2308-11. PubMed ID: 25242775
[TBL] [Abstract][Full Text] [Related]
18. Immunoglobulin, nucleos(t)ide analogues and hepatitis B virus recurrence after liver transplant: A meta-analysis.
Lai Q; Mennini G; Giovanardi F; Rossi M; Giannini EG
Eur J Clin Invest; 2021 Aug; 51(8):e13575. PubMed ID: 33866547
[TBL] [Abstract][Full Text] [Related]
19. Transplantation of hepatitis D virus patients: Lifelong hepatitis B immunoglobulins?
Ferenci P; Reiberger T; Stadlbauer V; Zoller H
Liver Int; 2023 Aug; 43 Suppl 1():96-100. PubMed ID: 35767373
[TBL] [Abstract][Full Text] [Related]
20. Complete hepatitis B virus prophylaxis withdrawal in hepatitis B surface antigen-positive liver transplant recipients after longterm minimal immunosuppression.
Lenci I; Baiocchi L; Tariciotti L; Di Paolo D; Milana M; Santopaolo F; Manzia TM; Toti L; Svicher V; Tisone G; Perno CF; Angelico M
Liver Transpl; 2016 Sep; 22(9):1205-13. PubMed ID: 27272189
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
